Life science company Avadim Technologies said yesterday it inked a deal withCardinal Health (NYSE:CAH) to distribute Avadim’s Theraworx topical bionome therapies designed to prevent catheter-associated urinary tract infections and complications.
The companies said that the Theraworx topical solution will compliment Cardinal Health’s Dover urological portfolio.
“We are honored to partner with one of the most influential leaders in healthcare across the globe. Cardinal Health’s commitment to improving healthcare for more people, in more ways, and in more places than ever before is directly aligned with our company’s mission to serve others. It is through this partnership that we hope to bring our microbiome patented solutions to the millions of individuals who suffer every day from urogenital complications via the vast Cardinal Health customer-base, and we look forward to diligently working with their global team to improve clinical outcomes in acute and Long-Term Care customers everywhere,” Avadim CEO Steve Woody said in a press release.